Generics in Belgium industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2006-10, and forecast to 2015). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Belgium generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Highlights

For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included. The market value is evaluated at ex-factory prices. Market volume is quantified here as the percentage of the total ethical pharmaceutical market volume in a country or region which is accounted for by generic drugs. It is therefore a generics penetration rate measure, not an absolute measure of market volume. All currency conversions were calculated at constant average annual 2010 exchange rates.
The Belgian generics market had total revenue of $0.5 billion in 2010, representing a compound annual growth rate (CAGR) of 8.1% between 2006 and 2010.
Percentage of generics share in total pharma market increased with a CAGR of 12.1% between 2006-2010, to reach 19.33% of total pharma market in 2010.
The performance of the market is forecast to decelerate, with an anticipated CAGR of 6% for the five-year period 2010 - 2015, which is expected to drive the market to a value of $670.4 million by the end of 2015.

Features

Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Belgium

Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Belgium

Leading company profiles reveal details of key generics market players' global operations and financial performance

Add weight to presentations and pitches by understanding the future growth prospects of the Belgium generics market with five year forecasts by both value and volume

Macroeconomic indicators provide insight into general trends within the Belgium economy

Key Questions Answered

What was the size of the Belgium generics market by value in 2010?

What will be the size of the Belgium generics market in 2015?

What factors are affecting the strength of competition in the Belgium generics market?

How has the market performed over the last five years?

How large is Belgium's generics market in relation to its regional counterparts?

EXECUTIVE SUMMARY
MARKET OVERVIEW
- Market definition
- Research highlights
- Market analysis
MARKET VALUE
MARKET VOLUME
MARKET SEGMENTATION
FIVE FORCES ANALYSIS
- Summary
- Buyer power
- Supplier power
- New entrants
- Substitutes
- Rivalry
LEADING COMPANIES
- Bayer AG
- Novartis AG
- Omega Pharma NV
- Sanofi-Aventis Group
MARKET FORECASTS
- Market value forecast
- Market volume forecast
MACROECONOMIC INDICATORS
APPENDIX
- Methodology
- Industry associations
- Related Datamonitor research
- Disclaimer
ABOUT DATAMONITOR
- Premium Reports
- Summary Reports
- Datamonitor consulting
LIST OF TABLES
- Table 1: Belgium generics market value: $ million, 2006-10
- Table 2: Belgium generics market volume: % of total pharma volume, 2006-10
- Table 3: Belgium generics market segmentation: % share, by value, 2010
- Table 4: Bayer AG: key facts
- Table 5: Bayer AG: key financials ($)
- Table 6: Bayer AG: key financials (€)
- Table 7: Bayer AG: key financial ratios
- Table 8: Novartis AG: key facts
- Table 9: Novartis AG: key financials ($)
- Table 10: Novartis AG: key financial ratios
- Table 11: Omega Pharma NV: key facts
- Table 12: Omega Pharma NV: key financials ($)
- Table 13: Omega Pharma NV: key financials (€)
- Table 14: Omega Pharma NV: key financial ratios
- Table 15: Sanofi-Aventis Group: key facts
- Table 16: Sanofi-Aventis Group: key financials ($)
- Table 17: Sanofi-Aventis Group: key financials (€)
- Table 18: Sanofi-Aventis Group: key financial ratios
- Table 19: Belgium generics market value forecast: $ million, 2010-15
- Table 20: Belgium generics market volume forecast: % of total pharma volume, 2010-15
- Table 21: Belgium size of population (million), 2006-10
- Table 22: Belgium GDP (constant 2000 prices, $ billion), 2006-10
- Table 23: Belgium GDP (current prices, $ billion), 2006-10
- Table 24: Belgium inflation, 2006-10
- Table 25: Belgium consumer price index (absolute), 2006-10
- Table 26: Belgium exchange rate, 2006-10
LIST OF FIGURES
- Figure 1: Belgium generics market value: $ million, 2006-10
- Figure 2: Belgium generics market volume: % of total pharma volume, 2006-10
- Figure 3: Belgium generics market segmentation: % share, by value, 2010
- Figure 4: Forces driving competition in the generics market in Belgium, 2010
- Figure 5: Drivers of buyer power in the generics market in Belgium, 2010
- Figure 6: Drivers of supplier power in the generics market in Belgium, 2010
- Figure 7: Factors influencing the likelihood of new entrants in the generics market in Belgium, 2010
- Figure 8: Factors influencing the threat of substitutes in the generics market in Belgium, 2010
- Figure 9: Drivers of degree of rivalry in the generics market in Belgium, 2010
- Figure 10: Bayer AG: revenues & profitability
- Figure 11: Bayer AG: assets & liabilities
- Figure 12: Novartis AG: revenues & profitability
- Figure 13: Novartis AG: assets & liabilities
- Figure 14: Omega Pharma NV: revenues & profitability
- Figure 15: Omega Pharma NV: assets & liabilities
- Figure 16: Sanofi-Aventis Group: revenues & profitability
- Figure 17: Sanofi-Aventis Group: assets & liabilities
- Figure 18: Belgium generics market value forecast: $ million, 2010-15
- Figure 19: Belgium generics market volume forecast: % of total pharma volume, 2010-15

Pharmaceutical Market Research

Generics in Belgium